Key result
C-reactive protein is associated with poor prognosis in heart failure, but further studies are warranted before CRP-targeted therapy can be recommended for its management.
Why the study?
Does C-reactive protein-targeted therapy improve outcomes in patients with heart failure?
Does C-reactive protein-targeted therapy improve outcomes in patients with heart failure?
While CRP is a known prognostic marker in heart failure, evidence is currently insufficient to recommend CRP-targeted therapies.
CRP prognostic in HF without therapeutic role; leaves open targeted therapy trials.
Heart failure continues to be a major public health burden in the USA. With markedly high rates of morbidity and mortality upon diagnosis, effective treatment and prognosis are critical in the management of chronic heart failure. Growing evidence now supports the hypothesis that inflammation plays a key role in the progression and worsening of heart failure. Of the various inflammatory mediators identified, C-reactive protein, an acute phase inflammatory marker, has been associated with poor prognosis in patients with heart failure. Several interventional studies have been investigated to explore C-reactive protein modulation and potential treatment options and health outcomes; however, further studies are warranted before C-reactive protein-targeted therapy may be recommended in the management of heart failure.
No takes yet. Share an insight, caveat, or question.
Huynh et al. (2015) conducted a review in Heart failure. C-reactive protein-targeted therapy was evaluated. C-reactive protein is associated with poor prognosis in heart failure, but further studies are warranted before CRP-targeted therapy can be recommended for its management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: